Sobi receives orphan drug designation for Elocta in Switzerland

17-Apr-2015 - Switzerland

Swedish Orphan Biovitrum AB has received Orphan Drug Designation in Switzerland for its long acting haemophilia drug candidate Elocta (rFVIIIFc) developed for the treatment of haemophilia A. An orphan drug designation is to encourage the development of medicines for rare diseases and provides orphan status to drugs and biologics under development.

Haemophilia is an inherited condition that influences the blood's ability to clot. The most common type of the condition is haemophilia A, where people lack clotting factor FVIII. The symptoms can be mild to severe, depending on the level of clotting factor. People with haemophilia bleed for longer than usual and in severe haemophilia, internal bleeding around joints and muscles are frequent. This causes pain, stiffness and may lead to joint damage. Haemophilia A is a rare disease, occuring in 1 of 5.000 male births.

Other news from the department research and development

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?